NanoString launches readout technology for NGS

By The Science Advisory Board staff writers

August 3, 2020 -- NanoString Technologies has released Cancer Transcriptome Atlas, a new product based on the company's GeoMx digital spatial profiler (DSP) platform that's optimized for readout on Illumina's next-generation sequencing (NGS) technology.

The NGS readout allows for increases of RNA- and protein-plexing using GeoMx DSP in combination with new software and assays. The new system is compatible with a variety of Illumina sequencers including MiSeq, NextSeq, HiSeq, and NovaSeq instruments.

NanoString plans to offer a portfolio of spatially resolved protein assays ranging from targeted content to whole transcriptome panels. Cancer Transcriptome Atlas is the first commercial GeoMx product that will be enabled by readout using NGS. It includes over 1,800 genes and 100 pathways and provides a 20-fold increase in RNA coverage resulting in a high-resolution spatial view of cancer biology.

The company will provide a full end-to-end solution by providing library preparation reagents and a bioinformatics pipeline that links the high-resolution, full-slide tissue images generated on GeoMx DSP with the output of Illumina sequencers.

Illumina introduces sequencing software for rare genetic diseases
Illumina has launched software that facilitates whole genome sequencing for rapid identification of rare genetic diseases.
Illumina Accelerator announces new genomics startups
Illumina has chosen seven companies to join the first global cohort of Illumina Accelerator, its startup incubator that partners with entrepreneurs to...
Imagia, Illumina partner to advance precision medicine
Healthcare artificial intelligence firm Imagia is partnering with Illumina on a project to further advance the development of precision medicine using...
NanoString debuts products to push COVID-19 research
NanoString Technologies has debuted new products that advance COVID-19 research by studying the immune response of the SARS-CoV-2 virus.

Copyright © 2020

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter